期刊文献+

31例伏立康唑不良反应/事件文献分析 被引量:23

Literature Analysis of 31 Adverse Drug Reaction/Event Cases Induced by Voriconazole
暂未订购
导出
摘要 目的探讨伏立康唑不良反应/事件的发生原因与规律,为临床安全用药提供参考。方法对31例国内文献报道的伏立康唑不良反应/事件进行统计和分析。结果男性患者多于女性,60岁以上患者占61.29%;64.52%的病例明确有合并用药情况,其中8例怀疑因合并用药引发不良反应/事件;不良反应/事件可发生在用药过程中和用药后的各个时间段,且累及多个系统-器官。结论临床医务人员应注意询问患者的过敏史,并结合患者的基因类型使用该药;应严格遵照说明书用药、及时进行药物浓度监测与加强药品不良反应监测。 Objective To discuss the causes and characteristics of the adverse drug reaction/event(ADR/ADE) cases induced by voriconazole in order to provide references for clinical rational drug use. Methods 31 ADR/ADE cases induced by voriconazole have been analyzed retrospectively. Results The number of male patients was more than the female. Patients over 60 years old accounted for 61.29%. 64.52% of the patients had combined medication, and it's suspected that concomitant medication resulted in 8 ADR/ADE cases. ADR/ADE can occur in the course of medication and after medication. The ADR/ADE involving multiple systems and organs. Conclusion Clinicians should pay attention to allergies and the genetic type of patients. The drug instruction should be adhered to. Drug monitoring should be timely done. The monitoring of adverse drug reactions should been strengthened.
作者 邹箴蕾
出处 《中国药物警戒》 2013年第10期623-626,共4页 Chinese Journal of Pharmacovigilance
关键词 伏立康唑 不良反应 事件 文献分析 voriconazole adverse drug reaction/event literature analysis
  • 相关文献

参考文献7

二级参考文献87

  • 1刘玮,杨新良,王雪松,王俊,蔡璐,郁祁.国产伏立康唑治疗耐氟康唑念珠菌深部感染疗效观察[J].临床药物治疗杂志,2007,5(1):32-34. 被引量:7
  • 2许向阳,朱家壁.群体药动学的研究进展及应用[J].中国医院药学杂志,2007,27(4):521-523. 被引量:9
  • 3Johnson LB,Kauffman CA.Voriconazole:a new triazole antifungal agent[J].Clin Infect Dis,2003,36(5):630-637.
  • 4Zonios DI,Gea-Banacloche J,Childs R,et al.Hallucinations during voriconazole therapy[J].Clin Infect Dis,2008,47(1):e7-e10.
  • 5Kadikoy H,Barkmeier A,Peck B,et al.Persistent photopsia following course of oral voriconazole[J].J Ocul Pharmacol Ther,2010,26(4):387-388.
  • 6Eiden C,Peyriere H,Cociglio M,et al.Adverse effects of voriconazole:analysis of the French Pharmacovigilance Database[J].Ann Pharmacother,2007,41(5):755-763.
  • 7Tan K,Brayshaw N,Tomaszewski K,et al.Investigation of the potential relationships between plasma vorieonazole concentrations and visual adverse events or liver function test abnormalities[J].J Glin Pharmacol,2006,46(2):235-243.
  • 8Imataki O,Ohnish H,Kitanaka A,et al.Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population[J].Int J Hematol,2008,88(1):3-6.
  • 9Smith J,Safdar N,Knasinski V,et al.Voriconazole therapeutic drug monitoring[J].Antimicrob Agents Chemother,2006,50(4):1570-1572.
  • 10Keady S,Thacker M.Voriconazole in the treatment of in-vasive fungal infections[J].Intensive Crit Care Nurs,2005,21(6):370.

共引文献123

同被引文献159

引证文献23

二级引证文献108

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部